CEMIinactive

CHEMBIO DIAGNOSTICS, INC.

Healthcare·Respiratory·Pre-clinical
Respiratory

CHEMBIO DIAGNOSTICS, INC. (CEMI): 13 pipeline candidates · ~29 mo cash runway. Updated within the last hour.

6.6/10

BioSniper Score

4-factor signal · derived from public data

Cash Runway8.0

28.9 months

Financial Health6.2

D/E 2.52 · 0% dilution

Pipeline Maturity2.0

Lead: Preclinical

Pipeline Breadth10.0

13 candidates

Catalyst MomentumN/A

N/A

Insider SignalN/A

N/A

A transparent, data-derived signal for CHEMBIO DIAGNOSTICS, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

Cash

$18.2M

Quarterly Burn

$2.8M

Runway

28.9 mo

Revenue

$10.3M

Cash Runway vs Catalysts

Tracked catalysts land within the current projected cash runway.

Cash ends ~Nov 2028
Today~32 mo out
Catalyst within runway

Pipeline (13 candidates)

Showing 10 of 13 candidates. Sign up for full pipeline.

·CEO: To Stockholders

Frequently asked questions

How many drug candidates are in CHEMBIO DIAGNOSTICS, INC.'s pipeline?

CHEMBIO DIAGNOSTICS, INC. (CEMI) has 13 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.

What is CHEMBIO DIAGNOSTICS, INC.'s lead drug candidate?

CHEMBIO DIAGNOSTICS, INC.'s most advanced tracked candidate is dpp respiratory antigen panel (Preclinical) for Respiratory infections.

What is CHEMBIO DIAGNOSTICS, INC.'s cash runway?

Based on its most recent reported cash balance and quarterly burn rate, CHEMBIO DIAGNOSTICS, INC. has approximately 28.9 months of cash runway.

Who is the CEO of CHEMBIO DIAGNOSTICS, INC.?

To Stockholders is the chief executive officer of CHEMBIO DIAGNOSTICS, INC. (CEMI).

Get the full picture on CHEMBIO DIAGNOSTICS, INC.

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.